Abbott Gabitril
Executive Summary
Cephalon will co-promote the anti-epileptic Gabitril (tiagabine) beginning in September. The company will increase its neurology sales force, which markets the narcolepsy therapy Provigil (modafinil), from 45 to 85 for the launch. Abbott also has an option to co-promote Provigil if Cephalon seeks a U.S. marketing partner
You may also be interested in...
Cephalon Provigil Reformulation Will Be Filed With FDA By Year-End
Cephalon's $100 mil. in new financing from a preferred stock offering finalized on Aug. 13 will help tide the company over while it develops new indications for its lead drug, wakefulness agent Provigil.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011